Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial
Introduction: Cardiovascular diseases have become the leading cause of death around the globe and diabetes mellitus (DM) is considered to be a coronary artery disease (CAD) risk equivalent. Ranolazine, an anti anginal drug has been found to reduce Glycated haemoglobin (HbA1c) in diabetes patient...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2015-01-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5448/10594_CE(RA1)_F(T)_PF1(NJAK)_PF2(PAK)_PFA(AK)_PF2(PAG).pdf |
| _version_ | 1818514977233829888 |
|---|---|
| author | Sandhiya Selvarajan Steven Aibor Dkhar Ajith Ananthakrishna Pillai Melvin George Balachander Jayaraman Adithan Chandrasekaran |
| author_facet | Sandhiya Selvarajan Steven Aibor Dkhar Ajith Ananthakrishna Pillai Melvin George Balachander Jayaraman Adithan Chandrasekaran |
| author_sort | Sandhiya Selvarajan |
| collection | DOAJ |
| description | Introduction: Cardiovascular diseases have become the leading
cause of death around the globe and diabetes mellitus (DM) is
considered to be a coronary artery disease (CAD) risk equivalent.
Ranolazine, an anti anginal drug has been found to reduce Glycated
haemoglobin (HbA1c) in diabetes patients with chronic angina.
However the effect of another antianginal drug trimetazidine, on
glycemic status is not clear.
Aim: To compare the effect of ranolazine and trimetazidine on
glycemic status in diabetic patients with CAD.
Settings and Design: Patients diagnosed with CAD and
diabetes mellitus attending Cardiology Out Patient Department
(OPD), Jawaharlal Institute of Postgraduate Medical Education
& Research (JIPMER), Puducherry, India were recruited for this
randomized open label parallel arm trial.
Materials and Methods: The study conducted from January2012 to April-2013 had 47 eligible patients diagnosed with CAD
and diabetes mellitus. They were randomized to receive either
ranolazine 500 mg BD or trimetazidine 35 mg BD for 12 weeks.
HbA1c levels, fasting blood glucose (FBG), lipid profile, QT and QTc
intervals were measured at baseline and after 12 weeks.
Statistical Analysis: Unpaired t-test was used to compare the
baseline characteristics of between the groups while comparison
within the groups were done using Paired t-test. Wilcoxon and Mann
Whitney U-tests were used for non parametric data. Graph pad instat
version-3 was used for statistical analysis. Values were expressed as
mean ± SD. A p < 0.05 was considered statistically significant.
Results: The study could not find any change in HbA1c levels in
both ranolazine and trimetazidine groups. The adverse effects
reported from patients on ranolazine include angina, constipation,
postural hypotension, headache, dizziness, nausea and weakness
while patients on trimetazidine complained of constipation,
weakness, palpitations, angina, dizziness, nausea, dyspepsia,
headache, gastric discomfort, joint pain, etc.
Conclusion: In patients with chronic angina and diabetes mellitus
Ranolazine 500mg BD and Trimetazidine 35mg BD did not show
any effect on HbA1c and fasting blood glucose lebel. |
| first_indexed | 2024-12-11T00:23:00Z |
| format | Article |
| id | doaj.art-fc25b292049c4e6abe3f2031a79acf65 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-11T00:23:00Z |
| publishDate | 2015-01-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-fc25b292049c4e6abe3f2031a79acf652022-12-22T01:27:41ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2015-01-0191OC01OC0510.7860/JCDR/2015/10594.5448Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled TrialSandhiya Selvarajan0Steven Aibor Dkhar1Ajith Ananthakrishna Pillai2Melvin George3Balachander Jayaraman4Adithan Chandrasekaran5Assistant Professor, Department of Clinical Pharmacology, JIPMER, Puducherry, India.Professor, Department of Pharmacology, JIPMER, Puducherry, India.Associate Professor, Department of Cardiology, JIPMER, Puducherry, India.Assistant Professor, Cardiac Clinical Trials, Department of Cardiology, SRM Medical College Hospital & Research Centre, Kattankulathur, Chennai, India.Professor, Department of Cardiology, JIPMER, Puducherry, India.Senior Professor & Head, Department of Clinical Pharmacology, JIPMER, Puducherry, India.Introduction: Cardiovascular diseases have become the leading cause of death around the globe and diabetes mellitus (DM) is considered to be a coronary artery disease (CAD) risk equivalent. Ranolazine, an anti anginal drug has been found to reduce Glycated haemoglobin (HbA1c) in diabetes patients with chronic angina. However the effect of another antianginal drug trimetazidine, on glycemic status is not clear. Aim: To compare the effect of ranolazine and trimetazidine on glycemic status in diabetic patients with CAD. Settings and Design: Patients diagnosed with CAD and diabetes mellitus attending Cardiology Out Patient Department (OPD), Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India were recruited for this randomized open label parallel arm trial. Materials and Methods: The study conducted from January2012 to April-2013 had 47 eligible patients diagnosed with CAD and diabetes mellitus. They were randomized to receive either ranolazine 500 mg BD or trimetazidine 35 mg BD for 12 weeks. HbA1c levels, fasting blood glucose (FBG), lipid profile, QT and QTc intervals were measured at baseline and after 12 weeks. Statistical Analysis: Unpaired t-test was used to compare the baseline characteristics of between the groups while comparison within the groups were done using Paired t-test. Wilcoxon and Mann Whitney U-tests were used for non parametric data. Graph pad instat version-3 was used for statistical analysis. Values were expressed as mean ± SD. A p < 0.05 was considered statistically significant. Results: The study could not find any change in HbA1c levels in both ranolazine and trimetazidine groups. The adverse effects reported from patients on ranolazine include angina, constipation, postural hypotension, headache, dizziness, nausea and weakness while patients on trimetazidine complained of constipation, weakness, palpitations, angina, dizziness, nausea, dyspepsia, headache, gastric discomfort, joint pain, etc. Conclusion: In patients with chronic angina and diabetes mellitus Ranolazine 500mg BD and Trimetazidine 35mg BD did not show any effect on HbA1c and fasting blood glucose lebel.https://jcdr.net/articles/PDF/5448/10594_CE(RA1)_F(T)_PF1(NJAK)_PF2(PAK)_PFA(AK)_PF2(PAG).pdfglycemic statushba1cqtcranolazinetrimetazidine |
| spellingShingle | Sandhiya Selvarajan Steven Aibor Dkhar Ajith Ananthakrishna Pillai Melvin George Balachander Jayaraman Adithan Chandrasekaran Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial Journal of Clinical and Diagnostic Research glycemic status hba1c qtc ranolazine trimetazidine |
| title | Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial |
| title_full | Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial |
| title_fullStr | Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial |
| title_full_unstemmed | Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial |
| title_short | Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial |
| title_sort | comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease a randomized controlled trial |
| topic | glycemic status hba1c qtc ranolazine trimetazidine |
| url | https://jcdr.net/articles/PDF/5448/10594_CE(RA1)_F(T)_PF1(NJAK)_PF2(PAK)_PFA(AK)_PF2(PAG).pdf |
| work_keys_str_mv | AT sandhiyaselvarajan comparisonofranolazineandtrimetazidineonglycemicstatusindiabeticpatientswithcoronaryarterydiseasearandomizedcontrolledtrial AT stevenaibordkhar comparisonofranolazineandtrimetazidineonglycemicstatusindiabeticpatientswithcoronaryarterydiseasearandomizedcontrolledtrial AT ajithananthakrishnapillai comparisonofranolazineandtrimetazidineonglycemicstatusindiabeticpatientswithcoronaryarterydiseasearandomizedcontrolledtrial AT melvingeorge comparisonofranolazineandtrimetazidineonglycemicstatusindiabeticpatientswithcoronaryarterydiseasearandomizedcontrolledtrial AT balachanderjayaraman comparisonofranolazineandtrimetazidineonglycemicstatusindiabeticpatientswithcoronaryarterydiseasearandomizedcontrolledtrial AT adithanchandrasekaran comparisonofranolazineandtrimetazidineonglycemicstatusindiabeticpatientswithcoronaryarterydiseasearandomizedcontrolledtrial |